Last reviewed · How we verify

Placebo of GB-0998

Japan Blood Products Organization · Phase 3 active Small molecule

Placebo of GB-0998 is a Small molecule drug developed by Japan Blood Products Organization. It is currently in Phase 3 development.

A placebo control arm in a clinical trial for GB-0998, containing no active pharmaceutical ingredient.

At a glance

Generic namePlacebo of GB-0998
SponsorJapan Blood Products Organization
ModalitySmall molecule
PhasePhase 3

Mechanism of action

As a placebo, this formulation is inert and serves as a control comparator in phase 3 trials to assess the efficacy and safety of the active GB-0998 drug candidate. Placebos are used to establish baseline disease progression and distinguish true drug effects from natural disease course and observer/patient bias.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo of GB-0998

What is Placebo of GB-0998?

Placebo of GB-0998 is a Small molecule drug developed by Japan Blood Products Organization.

How does Placebo of GB-0998 work?

A placebo control arm in a clinical trial for GB-0998, containing no active pharmaceutical ingredient.

Who makes Placebo of GB-0998?

Placebo of GB-0998 is developed by Japan Blood Products Organization (see full Japan Blood Products Organization pipeline at /company/japan-blood-products-organization).

What development phase is Placebo of GB-0998 in?

Placebo of GB-0998 is in Phase 3.

Related